Home  »  Business   »  What Do Analysts Say About BioMarin Pharmaceutical...

What Do Analysts Say About BioMarin Pharmaceutical Inc. (BMRN)?

How have the shares performed?

BioMarin Pharmaceutical Inc. (BMRN) saw an uptrend of 0.63% in the recent trading with $82.48 being its most recent. The current price level -37.49% lower than the highest price of $131.95 marked by the stock while trading over the past 52-weeks, whereas it is 15.60% higher than the lowest price of $71.35 the company dropped to over past 52-weeks. The latest news story on BMRN appeared in PR Newswire under the title “BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference” on Jun-15-21.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Squeezing the time span to 30 day period shows us the stock is currently trading -1.97% below one month high and is +8.88% above of the lowest during that time. Looking into the simple moving average, BioMarin Pharmaceutical Inc. (BMRN)’s stock stands at a SMA-50 of $78.61 while that of 5-day is reading $82.53.

Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and BMRN’s SMA-200 as of now is $79.51.

Do analysts rate it as a buy, sell or hold?

Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 23 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.

BioMarin Pharmaceutical Inc. Earnings – What Happened With BMRN

Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. BioMarin Pharmaceutical Inc. (BMRN) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of 228.60% for net revenue. During the reported three-month period, company’s sales were $488.79 billion while analysts on average were estimating the same to be $448.79 million.

BMRN – BioMarin Pharmaceutical Inc. Stock Earnings Estimates

The perspective of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.07 for stock’s EPS in the current quarter. 15 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was 0.09.

Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 181.77 million. BMRN does have institutional investors; and they hold 98.40% of the stock.

BioMarin Pharmaceutical Inc. – Insider Activity and Holdings

Moreover, the latest SEC filings also revealed that stock came across 23 new insider purchases involving 158,755 shares. On the other hand, BMRN declared 263,530 shares have been sold in 50 insider transactions over the past three months.

As on Mar 30, 2021, Capital Research Global Investors was the top most holder in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with an ownership of 22.08 million shares of the company or 12.08% of the stake worth $1.67 billion. The filing also reveals Primecap Management Company as the second largest holder in the company with a control over 9.94% of the outstanding shares. Its stake is worth $1.37 billion for having 18.16 million shares in hand.

Vanguard Group, Inc. (The) also came holding a key position in the company during the recent quarter and it now holds 8.95% of the outstanding shares. With this there are now 759 institutions which have possession in BMRN’s shares.

Currently, the stock has been recommended as Moderate Buy by 23 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.

The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by BioMarin Pharmaceutical Inc. was 4.76 while posting a debt to equity ratio of 0.00. The count was 27.27 for long-term debt to equity ratio.

BioMarin Pharmaceutical Inc.’s return on equity, or ROE, is 20.40%, compared to the industry average of -40.20% for Healthcare – Biotechnology. Although this indicates that BMRN uses its equity well, the metric will vary significantly depending on the industry.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Technical Analysis of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock

To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for BioMarin Pharmaceutical Inc. (BMRN), we notice that the stock’s 20-day average volume is at 835,145 shares. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 825,384 shares. And to end, BMRN’s 100-day average volume is 1,023,127 shares with 50% of the long-term indicators pointing towards Buy for the stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam